Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: MICE/TG.AC HEMI

P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)

TEF TRANSGENICS (PECDF)

**CAS Number:** 57117-31-4

C Number: C20201C

Lock Date: 07/24/2004

Cage Range: ALL

**Date Range:** ALL

**Reasons For Removal:** ALL

**Removal Date Range:** ALL

**Treatment Groups:** Include ALL Time Report Regsted: 15:27:08 First Dose M/F: NA / 04/21/03

Date Report Regsted: 06/14/2006

Lab: BAT

Test Type: 26-WEEK

**Route: SKIN APPLICATION** 

Species/Strain: MICE/TG.AC HEMI

# P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)

TEF TRANSGENICS (PECDF)

**CAS Number:** 57117-31-4

Date Report Reqsted: 06/14/2006

Time Report Reqsted: 15:27:08 First Dose M/F: NA / 04/21/03

Lab: BAT

TGAC (FVB/N) HEMIZYGOUS MICE FEMALE	0 NG/KG	72 NG/KG	242 NG/KG	720 NG/KG	1520 NG/KG
Disposition Summary					
Animals Initially in Study	20	20	20	20	20
Early Deaths Moribund Sacrifice Natural Death Survivors	1 2	4 3	3 1	7	6 1
Moribund Sacrifice Terminal Sacrifice Animals Examined Microscopically	17 20	13 20	16 20	13 20	1 12 20
ALIMENTARY SYSTEM					
Liver Mesentery Pancreas Salivary Glands	(20) (1) (0) (1)	(20) (1) (1) (0)	(20) (0) (0) (0)	(20) (0) (0) (0)	(20) (0) (0) (0)
Squamous Cell Carcinoma Stomach, Forestomach Squamous Cell Papilloma Squamous Cell Papilloma, Multiple	1 (100%) (6) 4 (67%) 1 (17%)	(2) 1 (50%) 1 (50%)	(2) 1 (50%) 1 (50%)	(5) 5 (100%)	(8) 4 (50%) 4 (50%)
Stomach, Glandular Tooth Odontogenic Tumor Odontogenic Tumor, Multiple	(1) (6) 5 (83%) 1 (17%)	(0) (6) 5 (83%) 1 (17%)	(0) (3) 2 (67%)	(0) (1)	(0) (2) 2 (100%)
CARDIOVASCULAR SYSTEM					
Heart	(0)	(0)	(0)	(0)	(1)
ENDOCRINE SYSTEM					
Pituitary Gland	(0)	(0)	(1)	(1)	(0)

### **GENERAL BODY SYSTEM**

None

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: 26-WEEK

**Route: SKIN APPLICATION** 

Species/Strain: MICE/TG.AC HEMI

## P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)

TEF TRANSGENICS (PECDF)

**CAS Number:** 57117-31-4

Time Report Reqsted: 15:27:08

First Dose M/F: NA / 04/21/03

Date Report Reqsted: 06/14/2006

Lab: BAT

CENITAL SYSTEM   None	GAC (FVB/N) HEMIZYGOUS MICE EMALE	0 NG/KG	72 NG/KG	242 NG/KG	720 NG/KG	1520 NG/KG
HEMATOPOIETIC SYSTEM	ITAL SYSTEM					
Lymph Node	one					
Spindle Cell Carcinoma, Metastatic, Skin, Site Of Application   1 (13%)	ATOPOIETIC SYSTEM					
Site Of Application   Squamous Cell Carcinoma, Metastatic, Lymph Node   Squamous Cell Carcinoma, Metastatic, Skin   3 (38%)   Mediastinal, Squamous Cell Carcinoma,   1 (13%)   1 (13%)   Mediastinal, Squamous Cell Carcinoma,   1 (13%)   Metastatic, Skin   1 (10 (10 (2) (3) (20) (20) (20) (20) (20) (20) (20) (20		(0)	(0)	(0)	(8) 1 (13%)	(4) 1 (25%)
Squamous Cell Carcinoma, Metastatic, Skin Mediastinal, Squamous Cell Carcinoma, Metastatic, Skin Thoracic, Squamous Cell Carcinoma, Metastatic, Skin Thoracic, Squamous Cell Carcinoma, Metastatic, Skin Thoracic, Squamous Cell Carcinoma, Metastatic, Skin Squamous Cell Carcinoma Squamous Cell Papilloma Squamous Cell Papilloma Squamous Cell Papilloma Squamous Cell Papilloma, Multiple Squamous Cell Papilloma, Multiple Squamous Cell Carcinoma Squamous Cell Carcinoma, Multiple Squamous Cell Carcinoma Squamous Cell Carcinoma, Multiple Squamous Cell Carcinoma Squamous Cell Carcinoma Squamous Cell Carcinoma Squamous Cell Carcinoma Squ	Site Of Application Squamous Cell Carcinoma, Metastatic,				, ,	1 (2370)
Metastatic, Skin           Thoracic, Squamous Cell Carcinoma, Metastatic, Skin           Lymph Node, Mandibular         (0)         (1)         (0)         (3)           Squamous Cell Carcinoma, Metastatic, Skin         (1)         (1)         (0)         (2)           Spleen         (20)         (20)         (20)         (20)         (20)           Thymus         (20)         (19)         (19)         (19)         (19)           INTEGUMENTARY SYSTEM           Skin         (4)         (4)         (8)         (7)           Squamous Cell Papilloma         4 (100%)         3 (38%)         1 (14%)           Squamous Cell Papilloma, Multiple         3 (43%)         3 (43%)           Skin, Control Dermis         (20)         (20)         (20)         (20)           Skin, Control Epidermis         (20)         (20)         (20)         (20)           Skin, Site Of Application         (20)         (20)         (20)         (20)           Keratoacanthoma         1 (5%)         1 (5%)         1 (5%)           Spindle Cell Carcinoma         1 (5%)         1 (5%)           Squamous Cell Carcinoma         1 (5%)         2 (10%)         5 (25%)	Squamous Cell Carcinoma, Metastatic, Skin					3 (75%)
Lymph Node, Mandibular (0) (1) (0) (3) Squamous Cell Carcinoma, Metastatic, Skin 1 (33%) Lymph Node, Mesenteric (1) (1) (1) (0) (2) Spleen (20) (20) (20) (20) (20) (20) (20) (20)	Metastatic, Skin				1 (1070)	1 (25%)
Lymph Node, Mesenteric Spleen (20) (20) (20) (20) (20) (20) (20) (20)	ymph Node, Mandibular	(0)	(1)	(0)	(3)	(3)
Spleen	Squamous Cell Carcinoma, Metastatic, Skin	(1)	(1)	(0)		1 (33%) (1)
Thymus (20) (19) (19) (19) (19) (19) (19) (19) (19					(20)	(20)
Skin       (4)       (4)       (8)       (7)         Squamous Cell Papilloma       4 (100%)       3 (38%)       1 (14%)         Squamous Cell Papilloma, Multiple       3 (43%)         Skin, Control Dermis       (20)       (20)       (20)         Skin, Control Epidermis       (20)       (20)       (20)       (20)         Skin, Site Of Application       (20)       (20)       (20)       (20)         Keratoacanthoma       1 (5%)       1 (5%)       1 (5%)         Spindle Cell Carcinoma       1 (5%)       1 (5%)       1 (5%)         Spindle Cell Carcinoma, Multiple       1 (5%)       2 (10%)       5 (25%)         Squamous Cell Carcinoma, Multiple       4 (20%)         Squamous Cell Carcinoma, Multiple       4 (20%)         Squamous Cell Papilloma       1 (5%)       5 (25%)       1 (5%)       1 (5%)						(18)
Squamous Cell Papilloma       4 (100%)       3 (38%)       1 (14%)         Squamous Cell Papilloma, Multiple       3 (43%)         Skin, Control Dermis       (20)       (20)       (20)         Skin, Control Epidermis       (20)       (20)       (20)       (20)         Skin, Site Of Application       (20)       (20)       (20)       (20)       (20)         Keratoacanthoma       1 (5%)       1 (5%)       1 (5%)         Spindle Cell Carcinoma       1 (5%)       1 (5%)       1 (5%)         Spindle Cell Carcinoma, Multiple       1 (5%)       2 (10%)       5 (25%)         Squamous Cell Carcinoma, Multiple       4 (20%)         Squamous Cell Papilloma       1 (5%)       5 (25%)       1 (5%)       1 (5%)	GUMENTARY SYSTEM					
Squamous Cell Papilloma, Multiple       3 (43%)         Skin, Control Dermis       (20) <td></td> <td>(4)</td> <td>(4)</td> <td></td> <td>(7)</td> <td>(13)</td>		(4)	(4)		(7)	(13)
Skin, Control Dermis       (20) <td< td=""><td></td><td></td><td>4 (100%)</td><td>3 (38%)</td><td></td><td>7 (54%) 5 (38%)</td></td<>			4 (100%)	3 (38%)		7 (54%) 5 (38%)
Skin, Control Epidermis       (20)		(20)	(20)	(20)		(20)
Keratoacanthoma       1 (5%)       1 (5%)         Spindle Cell Carcinoma       1 (5%)       1 (5%)         Spindle Cell Carcinoma, Multiple       5 (25%)         Squamous Cell Carcinoma, Multiple       4 (20%)         Squamous Cell Papilloma       1 (5%)       5 (25%)       1 (5%)	kin, Control Epidermis	(20)	(20)	(20)	(20)	(20)
Spindle Cell Carcinoma       1 (5%)       1 (5%)         Spindle Cell Carcinoma, Multiple       1 (5%)       2 (10%)       5 (25%)         Squamous Cell Carcinoma, Multiple       4 (20%)         Squamous Cell Papilloma       1 (5%)       5 (25%)       1 (5%)       1 (5%)		(20)	(20)	(20)		(20)
Spindle Cell Carcinoma, Multiple         Squamous Cell Carcinoma       1 (5%)       2 (10%)       5 (25%)         Squamous Cell Carcinoma, Multiple       4 (20%)         Squamous Cell Papilloma       1 (5%)       5 (25%)       1 (5%)       1 (5%)			1 (5%)	4 (50/)		2 (450/)
Squamous Cell Carcinoma       1 (5%)       2 (10%)       5 (25%)         Squamous Cell Carcinoma, Multiple       4 (20%)         Squamous Cell Papilloma       1 (5%)       5 (25%)       1 (5%)       1 (5%)				1 (3%)	1 (5%)	3 (15%) 1 (5%)
Squamous Cell Carcinoma, Multiple       4 (20%)         Squamous Cell Papilloma       1 (5%)       5 (25%)       1 (5%)       1 (5%)			1 (5%)	2 (10%)	5 (25%)	5 (25%)
Squamous Cell Papilloma 1 (5%) 5 (25%) 1 (5%) 1 (5%)	Squamous Cell Carcinoma, Multiple			, ,	4 (20%)	7 (35%)
0	Squamous Cell Papilloma	1 (5%)				00 (4655)
Squamous Cell Papilloma, Multiple       10 (50%)       16 (80%)       19 (95%)         Skin, Soa No Mass       (20)       (20)       (17)       (13)		(20)				20 (100%) (12)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: 26-WEEK

**Route: SKIN APPLICATION** 

Species/Strain: MICE/TG.AC HEMI

### P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)

TEF TRANSGENICS (PECDF)

**CAS Number:** 57117-31-4

Date Report Reqsted: 06/14/2006

Time Report Reqsted: 15:27:08 First Dose M/F: NA / 04/21/03

Lab: BAT

TGAC (FVB/N) HEMIZYGOUS MICE FEMALE	0 NG/KG	72 NG/KG	242 NG/KG	720 NG/KG	1520 NG/KG
MUSCULOSKELETAL SYSTEM					
None					
NERVOUS SYSTEM					
None					
RESPIRATORY SYSTEM					
Lung Alveolar/Bronchiolar Adenoma Squamous Cell Carcinoma, Metastatic, Skin	(20) 1 (5%)	(20)	(20)	(20) 1 (5%) 1 (5%)	(20) 1 (5%) 2 (10%)
SPECIAL SENSES SYSTEM					
None					
URINARY SYSTEM					
Kidney	(0)	(0)	(0)	(0)	(1)
SYSTEMIC LESIONS					
Multiple Organs Leukemia Erythrocytic	*(20) 1 (5%)	*(20)	*(20)	*(20) 1 (5%)	*(20)
Leukemia Granulocytic Leukemia Granulocytic Myelodysplasia	1 (3 <i>70)</i>			1 (070)	1 (5%) 1 (5%)

a - Number of animals examined microscopically at site and number of animals with lesion

<sup>\*</sup> Number of animals with any tissue examined microscopically

Test Type: 26-WEEK

**Route: SKIN APPLICATION** 

Species/Strain: MICE/TG.AC HEMI

P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)

TEF TRANSGENICS (PECDF) **CAS Number:** 57117-31-4

Time Report Reqsted: 15:27:08

First Dose M/F: NA / 04/21/03

Date Report Regsted: 06/14/2006

Lab: BAT

TGAC (FVB/N) HEMIZYGOUS MICE FEMALE	0 NG/KG	72 NG/KG	242 NG/KG	720 NG/KG	1520 NG/KG
Tumor Summary for Females					
Total Animals with Primary Neoplasms (b)	11	17	18	20	20
Total Primary Neoplasms	15	29	27	42	60
Total Animals with Benign Neoplasms	6	16	17	20	20
Total Benign Neoplasms	7	22	22	31	41
Total Animals with Malignant Neoplasms	2	1	3	9	15
Total Malignant Neoplasms	2	1	3	11	17
Total Animals with Metastatic Neoplasms				5	5
Total Metastatic Neoplasms				8	8
Total Animals with Malignant Neoplasms Uncertain Primary Site					
Total Animals with Neoplasms Uncertain-Benign or Malignant	6	6	2		2
Total Uncertain Neoplasms	6	6	2		2

\*\*\* END OF REPORT \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion b - Primary tumors: all tumors except metastatic tumors